S
SI-BONE, Inc. (SIBN)
NGM – Real Time Price. Currency in USD
13.90
+2.29 (19.72%)
At close: May 12, 2026, 4:00 PM EDT
13.95
+0.05 (0.34%)
After-hours: May 12, 2026, 7:57 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
13.90
+2.29 (19.72%)
At close: May 12, 2026, 4:00 PM EDT
13.95
+0.05 (0.34%)
After-hours: May 12, 2026, 7:57 PM EDT
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
| Name | Position |
|---|---|
| Dr. Daniel Joseph Cher M.D. | Senior Vice President of Clinical, Regulatory Affairs & Quality |
| Dr. Scott A. Yerby Ph.D. | Senior VP of Engineering & CTO |
| Dr. W. Carlton Reckling M.D. | Chief Medical Officer & VP of Medical Affairs |
| Mr. Anshul Maheshwari | COO & CFO |
| Mr. Anthony J. Recupero | Advisor |
| Mr. Ian Bailey | Vice President of Product & Marketing |
| Mr. Jeffrey W. Dunn | Executive Chairman |
| Mr. Michael A. Pisetsky J.D. | Chief Business & Legal Affairs Officer, Secretary and General Counsel |
| Mr. Saqib Iqbal | Vice President of Financial Planning & Analysis and Investor Relations |
| Ms. Laura A. Francis MBA | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-04-21 | DEFA14A | sibnproxy2026notice.htm |
| 2026-02-24 | S-8 | s-8evergreenfebruary26_fy26.htm |
| 2026-02-24 | 10-K | sibn-20251231.htm |
| 2026-02-23 | 8-K | sibn-20260220.htm |
| 2026-01-12 | 8-K | sibn-20260112.htm |
| 2025-11-10 | 10-Q | sibn-20250930.htm |
| 2025-08-05 | 10-Q | sibn-20250630.htm |
| 2025-08-04 | 8-K | sibn-20250731.htm |
| 2025-06-06 | 8-K | sibn-20250605.htm |
| 2025-05-06 | 10-Q | sibn-20250331.htm |